KEY OPINION LEADERS REVIEW CASE SCENARIOS IN TARGETED ONCOLOGYTM LIVE DISCUSSIONS
Necessity of Transplant Considered in Multiple MyelomaFebruary 9th 2021
Sagar Lonial, MD, a professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, and the chief medical officer of Winship Cancer Institute of Emory University, explains the need for transplant in patients with multiple myeloma.
Emerging Prognostic Tools for Myelofibrosis Further Refine Disease StatusFebruary 2nd 2021
Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, reviewed the prognostic tools used to find indicators of response to treatment in patients with myelofibrosis, during a Targeted Oncology Case-Based Peer Perspective Roundtable discussion.
Data From the RESPONSE Studies Drive Ruxolitinib Use in Polycythemia VeraJanuary 27th 2021
The way I practice, personally, is that if they are older than 60 years, they are automatically high risk, and I will start hydroxyurea. In PV, being over 60 years and/or prior thrombosis automatically makes the patient high risk, so you should probably be starting a cytoreductive therapy.